AL-'AQAR HEALTHCARE REIT |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.28 MYR | +0.79% |
|
-0.78% | +3.23% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- This company will be of major interest to investors in search of a high dividend stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Specialized REITs
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +3.23% | 229M | - | ||
| +3.91% | 693M | C+ | ||
| -6.42% | 608M | - | - | |
| -17.31% | 547M | - | - | |
| -6.94% | 392M | - | - | |
| -14.04% | 385M | - | - | |
| -23.25% | 309M | - | - | |
| -13.04% | 287M | - | - | |
| +0.16% | 231M | - | - | |
| -23.52% | 182M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- ALAQAR Stock
- Ratings Al-'Aqar Healthcare REIT
